Literature DB >> 1617643

Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2.

L Suardet1, A C Gaide, J M Calmès, B Sordat, J C Givel, J F Eliason, N Odartchenko.   

Abstract

We have established 3 new human colorectal cancer cell lines (LS411N, LS513, and LS1034) from clinical biopsy samples. These lines are tumorigenic and grow s.c. as adenocarcinomas in nude mouse xenografts. Specific marker chromosomes are observed in each line. Carcinoembryonic antigen is expressed at the surface of all 3 lines, but with marked quantitative differences. Indeed, less than 10% of the cells from the HT-29 line used as a reference express carcinoembryonic antigen while more than 90% of the LS1034 cells do so. LS513 and LS1034 consistently express HLA class I antigens and intercellular adhesion molecule 1 which are not detected at the surface of the LS411N cells. No expression of HLA class II antigens DR, DQ, and DP has been measured on any of the lines. All three lines grow well in 5% fetal calf serum medium without addition of exogenous growth factors. The LS1034 line has been adapted to growth in serum-free conditions and exhibits increased clonogenicity when cells are seeded in serum-free methylcellulose medium, as compared with medium containing 5% fetal calf serum. The LS513 and LS1034 lines have proved to be of particular interest since they respond to the growth-inhibitory action of TGF-beta 1 and TGF-beta 2 in both liquid and semisolid medium. Both factors were, at pM concentrations, equipotent inhibitors of LS1034 cell proliferation. In contrast, higher concentrations of TGF-beta 1 are inhibitory for proliferation of LS513 cells, whereas TGF-beta 2 has no effect on the growth of these cells in liquid assay. On this basis, using appropriate anti-TGF-beta 1 and anti-TGF-beta 1 IgY, we developed a bioassay for TGF-beta 1 and TGF-beta 2. Two of the three lines have indeed been shown to produce latent-TGF-beta 1 activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1617643

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Effects of transforming growth factor-beta (isoforms 1-3) on amyloid-beta deposition, inflammation, and cell targeting in organotypic hippocampal slice cultures.

Authors:  M E Harris-White; T Chu; Z Balverde; J J Sigel; K C Flanders; S A Frautschy
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

2.  Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues.

Authors:  Matthias Steinert; Manja Wobus; Carsten Boltze; Alexander Schütz; Mandy Wahlbuhl; Jörg Hamann; Gabriela Aust
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells.

Authors:  S Zhou; P Buckhaults; L Zawel; F Bunz; G Riggins; J L Dai; S E Kern; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

4.  TGF beta-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein.

Authors:  R E Herrera; T P Mäkelä; R A Weinberg
Journal:  Mol Biol Cell       Date:  1996-09       Impact factor: 4.138

5.  Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.

Authors:  M J Browning; P Krausa; A Rowan; D C Bicknell; J G Bodmer; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

6.  Characterization of the influence of anti-hormone and/or anti-growth factor neutralizing antibodies on cell clone architecture and the growth of human neoplastic astrocytic cell lines.

Authors:  I Camby; I Salmon; S Rorive; T Gras; F Darro; A Kruczynski; A Danguy; J L Pasteels; R Kiss
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Characterization of distinct functional domains of transforming growth factor beta.

Authors:  J K Burmester; S W Qian; A B Roberts; A Huang; S Amatayakul-Chantler; L Suardet; N Odartchenko; J A Madri; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

8.  Highly lytic CD8+, alpha beta T-cell receptor cytotoxic T cells with major histocompatibility complex (MHC) class I antigen-directed cytotoxicity in beta 2-microglobulin, MHC class I-deficient mice.

Authors:  S Apasov; M Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

9.  Distinct morphological and mito-inhibitory effects induced by TGF-beta 1, HGF and EGF on mouse, rat and human hepatocytes.

Authors:  B Petersen; C J Yee; W Bowen; R Zarnegar; G K Michalopoulos
Journal:  Cell Biol Toxicol       Date:  1994-08       Impact factor: 6.691

10.  Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient.

Authors:  M Olive; S Untawale; R J Coffey; M J Siciliano; D M Wildrick; H Fritsche; S Pathak; L M Cherry; M Blick; P Lointier
Journal:  In Vitro Cell Dev Biol       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.